Skip to main content

A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function

Completed · Phase 1 · NCT06916078

Conditions: Liver Dysfunction, Healthy

At a glance

Research payments reported, 2025
$404,005
U.S. investigators named
3
Sites paid
5
Planned or actual enrollment
30

About the trial

Sponsor
Eli Lilly and Company
Tested
Lepodisiran (drug)
Dates
Started 2025-04-23; completion 2026-07-13
Results posted
Not yet

The main purpose of this study is to evaluate how much lepodisiran gets into the blood stream and how long it takes the body to get rid of it when given as a subcutaneous (SC) injection under the skin to participants with mild, moderate, or severe liver function impairment compared to participants with normal liver function. The study will also evaluate how well lepodisiran is tolerated and what side effects may occur in these participants. The study will last up to approximately 9 weeks, excluding screening.

From ClinicalTrials.gov, last updated 2026-08-19. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly and Company reported $404,005 in research payments for this study in 2025 (6 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Orlando Clinical Research Center Inc $169,418
  • American Research Corp Inc $159,154
  • Erg Holding Co LLC DBA St Louis Clinical Trials LLC $71,457
  • Biovin Enterprises LLC $2,166
  • The Texas Liver Institute $1,810

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.